Inovio Pharmaceuticals Inc
NASDAQ:INO

Watchlist Manager
Inovio Pharmaceuticals Inc Logo
Inovio Pharmaceuticals Inc
NASDAQ:INO
Watchlist
Price: 1.855 USD -0.27%
Market Cap: 48.4m USD
Have any thoughts about
Inovio Pharmaceuticals Inc?
Write Note

Operating Margin
Inovio Pharmaceuticals Inc

-58 609.8%
Current
-15 209%
Average
-7.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-58 609.8%
=
Operating Profit
-119.4m
/
Revenue
203.8k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Inovio Pharmaceuticals Inc
NASDAQ:INO
50.3m USD
-58 610%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
140.5B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116.8B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
136.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
Country US
Market Cap 50.3m USD
Operating Margin
-58 610%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.3B USD
Operating Margin
28%
Country US
Market Cap 140.5B USD
Operating Margin
19%
Country US
Market Cap 116.8B USD
Operating Margin
38%
Country US
Market Cap 104.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 136.4B AUD
Operating Margin
26%
Country US
Market Cap 78.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
No Stocks Found

Inovio Pharmaceuticals Inc
Glance View

Market Cap
48.3m USD
Industry
Biotechnology

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.

INO Intrinsic Value
7.245 USD
Undervaluation 74%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-58 609.8%
=
Operating Profit
-119.4m
/
Revenue
203.8k
What is the Operating Margin of Inovio Pharmaceuticals Inc?

Based on Inovio Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -58 609.8%.